Table 1 Information on GWASs for exposure and outcome
Traits | Cases | Controls | Year | Number of SNPs | Sample size | Population | PMID/Consortium |
|---|---|---|---|---|---|---|---|
IgA nephropathy | 977 | 4,980 | 2010 | 278,077 | 5,957 | European | 20,595,679 |
Membranous nephropathy | 2,150 | 5,829 | 2020 | 5,327,688 | 7,979 | European | 32,231,244 |
Glomerulonephritis | 4,613 | 214,179 | 2021 | 16,380,466 | 218,792 | European | IEU GWAS datasets |
Nephrotic syndrome | 480 | 214,619 | 2021 | 16,380,437 | 215,099 | European | IEU GWAS datasets |
Diabetic nephropathy | 3,283 | 181,704 | 2021 | 16,380,336 | 184,987 | European | IEU GWAS datasets |
Chronic kidney disease | 12,385 | 104,780 | 2016 | 2,191,877 | 117,165 | European | 26,831,199/ CKDGen |
Urolithiasis | 3,625 | 459,308 | 2018 | 9,851,867 | 462,933 | European | MRC-IEU |
210 kinds of T-cell traits and markers | - | - | 2018 | 10,534,735 | 3,757 | European | 3,292,928 |
Inflammatory bowel disease | 38,155 | 33,977 | 2015 | 157,116 | 86,640 | European | 26,192,919/ IIBDGC |
Crohn’s disease | 20,550 | 41,642 | 2015 | 124,888 | 62,192 | European | 26,192,919/ IIBDGC |
Ulcerative colitis | 17,647 | 47,179 | 2015 | 156,116 | 64,826 | European | 26,192,919/ IIBDGC |